WallStSmart
ACRV

Acrivon Therapeutics, Inc. Common Stock

NASDAQ: ACRV · HEALTHCARE · BIOTECHNOLOGY

$1.91
-7.74% today

Updated 2026-06-05

Market cap
$66.77M
P/E ratio
P/S ratio
EPS (TTM)
$-2.00
Dividend yield
52W range
$1 – $4
Volume
0.7M

Acrivon Therapeutics, Inc. Common Stock (ACRV) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$2.19M$106.59M$181.23M$138.26M$196.59M$129.72M
Cash & equivalents$1.58M$99.60M$29.52M$36.02M$39.82M$41.50M
Current assets$1.72M$100.41M$132.09M$129.69M$181.63M$120.44M
Total liabilities$10.60M$130.40M$10.75M$17.07M$19.80M$17.20M
Current liabilities$613000.00$2.91M$6.52M$13.30M$17.21M$15.66M
Long-term debt
Shareholder equity$-8.41M$-23.81M$170.47M$121.19M$176.79M$112.52M
Retained earnings$-8.62M$-24.86M$-56.03M$-116.42M$-196.98M$-274.88M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

How much free cash flow does ACRV generate?

ACRV produced $-65.33M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACRV's balance sheet healthy?

ACRV holds $41.50M in cash and equivalents against — in long-term debt, on $112.52M of shareholder equity. That debt is best read against the cash flow the business throws off each year.